Additionally, exosomal PD-L1 may allow tumor cells to evade immune surveillance even in the presence of PD-1/PD-L1 checkpoint inhibitors, ultimately leading to treatment resistance (Table 2) (Yin et al., 2021). This evidence concerns the gene CD274 and neoplasm.